当前位置:首页 > 报告详情

Zimmer biomet-jp-morgan-presentation-2026.pdf

上传人: 明**** 编号:1069786 2026-01-17 10页 824.81KB

1、January 2026From Turnaround to TransformationJP Morgan Presentation 20262DisclaimerCautionary Note Regarding Forward-Looking Statements:This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995,inclu

2、ding statements regarding sales and earnings,financial guidance,and any statements about our forecasts,expectations,plans,intentions,strategies or prospects.All statements other than statements of historical or current fact are,or may be deemed to be,forward-looking statements.Such statements are ba

3、sed upon the current beliefs,expectations and assumptions of management and are subject to significant risks,uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements.These risks,uncertainties and changes in circu

4、mstances include,but are not limited to:competition;pricing pressures;dependence on new product development,technological advances and innovation;changes in customer demand for our products and services caused by demographic changes,obsolescence,development of different therapies or other factors;ou

5、r ability to attract,retain,develop and maintain adequate succession plans for the highly skilled employees,senior management,independent agents and distributors we need to support our business;shifts in the product category or regional sales mix of our products and services;the risks and uncertaint

6、ies related to our ability to successfully execute our restructuring plans;control of costs and expenses;risks related to the ability to realize the anticipated benefits of our acquisitions,including the possibility that the expected benefits from such transactions will not be realized or will not b

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **业绩转折与转型**:2025年实现业绩反转,市场份额回升,员工敬业度提升($6.8B高敬业度评分),库存问题改善(<1天缺货)。 2. **产品与市场**:2025年髋关节(40%)、膝关节(35%)为核心品类,S.E.T.(27%)增长显著;2026年加速机器人(+3.5x)、门诊手术(+4x)等创新领域。 3. **财务目标**:2026年销售增长温和,EPS与销售同步,自由现金流增速快于EPS,持续回报股东。 4. **战略重点**:优化全球商业渠道(美国销售团队专业化)、运营效率(WAMGR降至~4%)、创新(碘处理髋关节系统、智能植入物等)。 5. **风险提示**:包含前瞻性声明,受竞争、供应链、监管等多重因素影响,实际结果可能存在差异。
**转型计划?** **增长动力?** **创新方向?**
客服
商务合作
小程序
服务号
折叠